NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03110562,"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma",https://clinicaltrials.gov/study/NCT03110562,BOSTON,COMPLETED,"This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.",YES,Multiple Myeloma,DRUG: Selinexor|DRUG: Bortezomib|DRUG: Dexamethasone,"SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC), PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%)., From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)","SVd/Vd Arm: Overall Response Rate (ORR) as Assessed by IRC, ORR was defined as the percentage of the participants who achieved any confirmed partial response (PR) or better PR, complete response (CR), very good partial response (VGPR) or stringent complete response (sCR) based on the IRC's response outcome assessments, according to the International Myeloma Working Group (IMWG) response criteria, before IRC-confirmed PD or initiating a new MM treatment. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined as Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry., From date of randomization until disease progression or initiating a new MM treatment (up to 33 months)|SVd/Vd Arm: Percentage of Participants With Response Rate of Very Good Partial Response (VGPR) or Better Based on IRC Assessment, Response rate was defined as percentage of participants with responses of VGPR, at any time prior to IRC-confirmed PD or initiating a new MM treatment. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours., From date of randomization until confirmed PD or initiating a new MM treatment (up to 33 months)|SVd/Vd Arm: Number of Participants With at Least One Grade Greater Than or Equal to [>=] 2 Peripheral Neuropathy Events, Peripheral neuropathy events was assessed using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The grade ranges from Grade 1 (mild, asymptomatic, or mild symptoms) to Grade 5 (death related to an adverse event). Grade 2 indicates a moderate condition that may require minimal intervention and can limit certain daily activities. Grade 3 represents severe symptoms that are not immediately life-threatening but may lead to hospitalization and restrict self-care activities. Grade 4 denotes life-threatening consequences requiring urgent intervention. Number of participants experiencing at least one Grade \>= 2 peripheral neuropathy event have been reported., From first dose of study treatment to 30 days after the last dose of study treatment inclusive, or the day before the start of new anti-MM treatment, whichever occurs first (up to 33 months)|SVd/Vd Arm: Overall Survival (OS), OS was defined as the time from the date of randomization until either the date of death due to any cause or until the participant is lost to follow-up, for all participants., From date of randomization to the date of death or censored date, whichever occurred first (up to 45 months)|SVd/Vd Arm: Duration of Response (DOR) as Assessed by IRC, DOR was defined as the duration of time from the first occurrence of an IRC confirmed response of at least (\>=) PR until the first date of IRC-confirmed PD or death due to any cause, whichever occurred first. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; PD: Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>= 5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method., From the first documentation of response to the first documentation of PD or death, whichever occurred first (up to 45 months)|SVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment, ORR was defined as the percentage of the participants who achieved a confirmed partial response or better (i.e., PR, VGPR, CR, or sCR) based on the IRC's response outcome assessments, according to the IMWG response criteria. PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or \<200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; or sCR: CR as defined as Normal FLC ratio+ Absence of clonal cells in bone marrow biopsy by immunohistochemistry., From date of first SVdX treatment until disease progression or initiating a new MM treatment (up to 33 months)|SVdX Arm: Progression Free Survival1 (PFS1) as Assessed by IRC During SVdX Treatment, PFS1 is defined as the duration of time from the date of the first dose of the SVd treatment after crossover from the Vd arm until the first date of PD or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%)., From date of first SVdX treatment until IRC-confirmed documented PD or death or censored date, whichever occurred first (up to 33 months)|SVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd, TTNT is defined as the duration from date of randomization to start of next anti-MM treatment or death, whichever occurs first. For patients without an event, their follow-up time will be censored at the date of discontinuation from study, or last participating visit on or before database cutoff date, whichever occurs first., From date of randomization to start of next anti-MM treatment or death, whichever occurred first (up to 33 months)|SVd/Vd Arm: Time To Response (TTR) in Participants Randomized to the SVd and Vd Arm, TTR was defined as duration from randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR) before IRC-confirmed PD or initiating a new MM treatment per IMWG response criteria. The participants who do not achieve IRC-confirmed PR or better response will be censored at the date of last disease assessment on or before database cutoff date. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry., From randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR), whichever occurred first (up to 33 months)|SVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment, PFS 2 was defined as the duration of time from the date of the first dose of the treatment after SVd/Vd/SVdX until the first date of PD on treatment after SVd/Vd/SVdX or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%)., From date of first dose of post-SVd/Vd/SVdX treatment to the date of first PD on post-SVd/Vd/SVdX treatment, or death due to any cause (up to 33 months)|SVd/Vd Arm: Change From Baseline in Participant-Reported Peripheral Neuropathy (PN) Assessed by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire- Chemotherapy-Induced PN 20 (EORTC- QLQ-CIPN20) Total Scores, The EORTC QLQ-CIPN20 instrument is a 20-item QoL instrument, which has been developed to elicit patients' experience of symptoms and functional limitations related to CIPN. The QLQ-CIPN20 contains 20 items assessing sensory (9 items), motor (8 items), and autonomic symptoms (3 items) containing a 4-point Likert scale (1= not at all, 2= a little, 3= quite a bit, and 4= very much), participants indicate the degree to which they have experienced sensory, motor, and autonomic symptoms during the past week. Sensory raw scale scores range from 1 to 36, motor raw scale scores range from 1 to 32, and autonomic raw scale scores range from 1 to 12 for men and 1-8 for women (erectile function item is excluded). All scale scores are linearly converted to a total score with range of 0-100 scale, with higher scores indicating more symptom burden., Svd Arm: Baseline up to End of treatment (EOT) (at Day 820); Vd Arm: Baseline up to EOT (at Day 848)",,Karyopharm Therapeutics Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,402,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,KCP-330-023,2017-05-24,2020-02-18,2022-05-12,2017-04-12,2021-07-08,2024-08-21,"Boca Raton Clinical Research (BRCR) Medical Center, Plantation, Florida, 33324, United States|Emory University, Atlanta, Georgia, 30322, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, 96817, United States|McFarland Clinic, Ames, Iowa, 50010, United States|Stormont Vail Health Care (Cotton O'Neil Cancer Center ), Topeka, Kansas, 66606, United States|Commonwealth Hematology, Danville, Kentucky, 40422, United States|Norton Cancer Institute, Louisville, Kentucky, 40202, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Central Care Cancer Center, Bolivar, Missouri, 65613, United States|The Valley Hospital Luckow Pavilion, Paramus, New Jersey, 07652, United States|Mount Sinai, New York, New York, 10029, United States|The Cancer Institute at St. Francis Hospital, Roslyn, New York, 11576, United States|Novant-Forsyth Memorial Hospital, Winston-Salem, North Carolina, 27103, United States|University of Cincinnati Health, Cincinnati, Ohio, 45267, United States|Southwest Cancer Center of Oklahoma, Lawton, Oklahoma, 73505, United States|Kaiser Permanente Northwest OR, Portland, Oregon, 97210, United States|SCOR AnMed Health Cancer Center, Anderson, South Carolina, 29621, United States|Prairie Lakes Healthcare, Watertown, South Dakota, 57201, United States|Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States|University of Texas Southwestern, Dallas, Texas, 75390, United States|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Mater Misericordiae Limited and Mater Medical Research, South Brisbane, Queensland, 4101, Australia|Gold Coast University Hospital, Southport, Queensland, 4215, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Austria|University Hospital Krems, Department of Internal Medicine II, Krems, Austria|Medical University of Vienna, Vienna, 1090, Austria|General Hospital Hietzing, Vienna, 1130, Austria|Wilhelminen Hospital, Department of Internal Medicine I, Center for Oncology & Hematology, Vienna, 1160, Austria|Jules Bordet Institute, Brussels, 1000, Belgium|UCL Saint-Luc, Brussels, Belgium|University Hospital Ghent, Ghent, 9000, Belgium|General Hospital Delta, Roeselare, 8800, Belgium|St. Augustinus Hospital, Wilrijk, 2610, Belgium|University Multiprofile Hospital for Active Treatment, Sveti Georgi Clinic of Clinical Hematology, Plovdiv, 4002, Bulgaria|University Multiprofile Hospital for Active Treatment, Sveti Ivan Rilski Clinic of Hematology, Sofia, 1431, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Clinic of Hematology, Dept. of Clinical Hematology, Sofia, 1756, Bulgaria|Tom Baker Cancer Center/ Alberta Health Services, Calgary, Alberta, T2N 4Z6, Canada|Cross Cancer Institute / University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada|Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, B3H 2Y9, Canada|North East Cancer Centre Sudbury, Sudbury, Ontario, P3E 5J1, Canada|Princess Margaret Cancer Research, Toronto, Ontario, M5G 1X5, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, H1T 2M4, Canada|Royal Victoria Hospital / McGill University, Montreal, Quebec, H3A 1A1, Canada|L'Hôtel-Dieu de Québec, Quebec City, Quebec, G1R 2J6, Canada|Saskatchewan Cancer Agency-Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7TI, Canada|Saskatoon Cancer Center, Saskatoon, Saskatchewan, S7N 4H4, Canada|General University Hospital in Prague, Praha 2, Prague, 128 08, Czechia|University Hopsital Brno, Brno, 625 00, Czechia|University Hospital Hradec Kralove, Hradec Kralove, 500 05, Czechia|University Hospital Olomouc, Olomouc, 775 20, Czechia|University Hospital Ostrava, Dept. of Hematooncology, Ostrava, 708 52, Czechia|University Hospital Kralovske Vinohrady, Clinic of Internal Hematology, Prague, 100 34, Czechia|Necker Children's Hospital, Department of Adult Hematology, Paris, Ile De France, 75015, France|Hospital Center Departmental La Roche-Sur-Yon, La Roche-sur-Yon, 85925, France|Claude Huriez Hospital, Lille, 59037, France|South Lyon Hospital Center, Lyon, 69002, France|Brabois Adults Hospital, University Hospital Center of Nancy, Nancy, 54511, France|Nantes University Hospital Center, Nantes, 44093, France|Saint-Louis Hospital, Paris, 75475, France|Miletrie Hospital, University Hospital Center of Poitiers, Poitiers, 86021, France|University Hospital Freiburg, Department of Internal Medicine I, Freiburg, Baden-Wuerttemberg, D-79106, Germany|Klinikum Leverkusen gGmbH Medizinisxhe Klinik 3, Leverkusen, North Rhine Westfalia, 51375, Germany|Group Practice for Hematology and Oncology, Dresden, Saxony, 1307, Germany|Alexandra General Hospital, Therapeutic Clinic, Athens, 11528, Greece|General Hospital of Athens ""Evangelismos"", Department of Hematology and Lymphoma, Athens, Greece|University General Hospital of Patra, Pátra, Greece|Theageneion Cancer Hospital, Hematology Department, Thessaloníki, 54639, Greece|Semmelweis University, 1st Department of Internal Medicine, Budapest, H-1083, Hungary|Integrated Szent Istvan and Szent laszlo Hospital, Department of Hematology and Stem Cell Transplantation, Budapest, H-1097, Hungary|Semmelweis University, 3rd Department of Internal Medicine, Budapest, H-1125, Hungary|Kaposi Mor Teaching Hospital, 2nd Department of Internal Medicine, Kaposvar, 7400, Hungary|Medical Center of the University of Pecs, Department of Hematology, Pecs, 7624, Hungary|Regional Cancer Centre, Patna, Bihar, 800014, India|Regional Cancer Centre, Thiruvananthapuram, Kerala, 695011, India|Prince Aly Khan Hospital, Mumbai, Maharashta, 400010, India|Jaslok Hospital and Research Centre, Mumbai, Maharashta, 400026, India|Bhaktivedanta Hospital, Thane, Maharashtra, 401107, India|IMS & SUM Hospital, Bhubaneswar, Odisha, 751003, India|Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, Punjab, 160012, India|Dayanand Medical College & Hospital, Ludhiana, Punjab, 141001, India|Cancer Institute, Chennai, Tamil Nadu, 600020, India|SRM Institute of Medical Sciences, Chennai, Tamil Nadu, 600026, India|Saveetha Medical College Hospital, Chennai, Tamil Nadu, 602105, India|G. Kuppuswamy Naidu Hospital, Coimbatore, Tamil Nadu, 641037, India|Asviratham Speciality Hospital, Madurai, Tamil Nadu, 625020, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, 625107, India|Yashoda Hospital, Hyderabad, Telengana, 500082, India|King George's Medical University, Lucknow, Uttar Pradesh, 226003, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, 700094, India|Nil Ratan Sircar (NRS) Medical College, Kolkata, West Bengal, 700120, India|TATA Memorial Centre, Kolkata, West Bengal, 700160, India|Rajiv Gandhi Cancer Hospital, New Delhi, 110085, India|Barzilai Medical Center, Ashkelon, 7830604, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petaẖ Tiqwa, 49100, Israel|Hospital Santa Maria of Terni, Terni, Umbria, 05100, Italy|Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, 60131, Italy|ASST Papa Giovanni XXIII, Bergamo, 24127, Italy|Polyclinic S. Orsola-Malpighi, Department of Hematology, Oncology and Laboratory Medicine, Operative Unit of Hematology - Cavo, Bologna, 40138, Italy|University Hospital Careggi, Department of Hematology, Florence, 50134, Italy|University Hospital San Martino, IRCCA, Dept. of Integrative Cancer Therapies, Operative Unit of Clinical Hematology, Genoa, 16132, Italy|Hospital Niguerda Ca Granda, Department of Hematology and Oncology, Hematology Unit, Milan, 20162, Italy|Umberto I Polyclinic of Rome, Department of Cellular Biotechnology and Hematology, Hematology Center, Rome, 00161, Italy|University Hospital San Giovanni Battista of Turin, Turin, 10126, Italy|Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology, Bydgoszcz, 85-168, Poland|Independent Public Healthcare Facility Municipal Hospital Group in Chorzow, Department of Hematology, Chorzow, 41-500, Poland|University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow, 31-501, Poland|Independent Public Teaching Hospital No.1 in Lublin, Department of Hematology-Oncology and Bone Marrow Transplantation, Lublin, 20-081, Poland|St. John of Dukla Oncology Center of Lublin, Department of Hematology, Lublin, 20-090, Poland|Military Institute of Medicine, Department of Internal Medicine and Hematology, Warsaw, 04-141, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Department of Hematology, Łódź, 93-513, Poland|Hyperclnical MedLife PDR Vulturului Brasov, Hematology Department, Braşov, 500366, Romania|Colentina Clinical Hospital, Department of Hematology, Bucharest, 020125, Romania|Bucharest University Emergency Hospital, Department of Hematology, Bucharest, 050098, Romania|S.P. Botkin City Clinical Hospital, Moscow, 125284, Russian Federation|N.A. Semashko Central Clinical Hospital #2 under OJSC Russian Railways, Moscow, 129128, Russian Federation|First I.P. Pavlov State Medical University of St. Petersburg, Saint Petersburg, 197022, Russian Federation|V.A. Almazov North-West Federal Medical Research Center, Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department #1, Saint Petersburg, 197341, Russian Federation|Clinical Center of Serbia, Clinic of Hematology, Belgrade, 11000, Serbia|Institute of Oncology and Radiology of Serbia, Clinic of Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Clinic of Hematology, Kragujevac, 34 000, Serbia|Clinical Center Nis, Clinic of Hematology and Clinical Immunology, Nis, 18 000, Serbia|Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, 21 000, Serbia|University Hospital of the Canary Islands, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Catalan Institute of Oncology (ICO) Badalona, Badalona, 08916, Spain|University Hospital of Vall d'Hebron, Barcelona, 08035, Spain|University Hospital Infanta Leonor, Department of Hematology, Madrid, 28301, Spain|University Clinical Hospital of Salamanca, Department of Hematology, Salamanca, 37007, Spain|University Hospital Virgen del Rocio (HUVR), Seville, 41013, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostic Hematology Center, Department of Hematology, Cherkasy, 18009, Ukraine|City Clinical Hospital No.4 of Dnipro City Council, City hematology center, Dnipropetrovsk, Ukraine|BMT Kiev Center, Kiev, Ukraine|Kiev Cancer Institute, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Department of Hematology with Laboratory Group, Lviv, 79044, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Department of Hematology, Vinnytsia, 21018, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Hematology Department with Intensive Therapy Wards, Zhytomyr, 10008, Ukraine|Belfast Heatlh & Social Care Trust Belfast City Hospital, Belfast, Northern Ireland, BT9 7AB, United Kingdom|NHS Tayside Ninewells Hospital, Dundee, Scotland, DD1 9SY, United Kingdom|Cardiff & Vale University Health Board University Hospital of Wales, Cardiff, Wales, CF14 4XW, United Kingdom|University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|The Leeds Teaching Hospitals NHS Trust St. James University Hospital, Leeds, LS9 7TF, United Kingdom|University Hospitals of Leicester NHS Trust Royal Leicester Infirmary, Leicester, LE1 5WW, United Kingdom|Royal Liverpool & Broadgreen University Hospital NHS Trust Royal Liverpool University Hospital, Liverpool, L7 8XP, United Kingdom|London North West Healthcare NHS Trust Northwick Park Hospital, London, HA1 3UJ, United Kingdom|University College London, London, NW3 2PF, United Kingdom|King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom|Imperial College Healthcare NHS Trust Hammersmith Hospital, London, W12 0HS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, NE7 7DN, United Kingdom|The Royal Wolverhampton NHS Trust New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/62/NCT03110562/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/62/NCT03110562/SAP_001.pdf"
